[Antiplatelet agents increase hemorrhagic risk in patients undergoing a cardiac pacemaker or ICD implantation]

Area of Science:

• Cardiology
• Medical Devices
• Pharmacology

Background:

• Cardiac stimulator and defibrillator implantation are common procedures.
• Antiplatelet agents are frequently used to prevent thrombotic events.
• The potential impact of antiplatelet therapy on peri-procedural bleeding risk in these patients is a critical concern.

Purpose of the Study:

• To evaluate the association between antiplatelet agent use and hemorrhagic complications during cardiac stimulator or defibrillator implantation/replacement.
• To compare bleeding risk in patients on antiplatelet agents versus a control group not receiving these medications.

Main Methods:

• Retrospective study including patients undergoing pacemaker or ICD implantation/replacement from January 2007 to May 2010.
• Primary endpoint: incidence of bleeding complications.
• Comparison of complication rates between patients on antiplatelet agents (aspirin, clopidogrel, or combination) and those not receiving them.

Main Results:

• A total of 685 patients were included; 214 (31%) received antiplatelet agents, and 471 (69%) did not.
• Hemorrhagic complications occurred in 7.5% of patients on antiplatelet agents versus 3% in the control group (P=0.004).
• Multivariable analysis identified implantable cardioverter-defibrillator (ICD) type (OR 3.7) and antiplatelet treatment (OR 2.7) as significant factors for increased bleeding risk.

Conclusions:

• Pacemaker and ICD implantation or replacement in patients taking antiplatelet agents are associated with an increased hemorrhagic risk.
• Antiplatelet therapy is a significant independent risk factor for bleeding complications in this patient population.
• The findings underscore the importance of risk-benefit assessment for antiplatelet agents in patients undergoing cardiac device procedures.